secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160340
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS
--------------------------------------------------------------------------------

- 100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.
- No treatment-related SAEs, DLTs, CRS, or ICANS reported; common TEAEs mild and linked to temozolomide.
- Cohort 1 PFS ranged 7.4–11.9 months; Cohort 3 first patient had 7.1 months PFS with no brain progression.
- Company on track to complete Phase 1 enrollment in 2023; further updates expected later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/0001193125-23-160340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523160340/d447037d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer